Pyridoxine for Prevention of Hand-Foot Syndrome Caused by Chemotherapy: A Systematic Review

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Chen, Min ^a,b   Zhang, Lingli ^a,b   Wang, Qian ^c   Shen, Jiantong ^c  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DOXORUBICIN; PLACEBO; PYRIDOXINE;

ARTICLE; BREAST CANCER; COLORECTAL CANCER; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM CANCER; HAND FOOT SYNDROME; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); OVARY CANCER; PERITONEUM CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STOMACH CANCER; SYSTEMATIC REVIEW; DRUG ADMINISTRATION; FEMALE; HAND-FOOT SYNDROME; MALE; META ANALYSIS; NEOPLASMS; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HAND-FOOT SYNDROME; HUMANS; MALE; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAMIN B 6;

EID: 84882709282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072245     Document Type: Article

References (29)

1. Gressett SM, Stanford BL, Hardwicke F, (2006) Management of hand-foot syndrome induced by capecitabine. Journal of Oncology Pharmacy Practice 12: 131-141.
2. Nagore E, Insa A, Sanmartín O, (2000) Antineoplastic Therapy-Induced Palmar Plantar Erythrodysesthesia ('Hand-Foot') Syndrome: Incidence, Recognition and Management. American Journal of Clinical Dermatology 1: 225-234.
3. Lipworth AD, Robert C, Zhu AX, (2009) Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77: 257-271.
4. von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, et al. (2008) Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44: 781-790.
5. Degen A, Alter M, Schenck F, Satzger I, Völker B, et al. (2010) The hand-foot-syndrome associated with medical tumor therapy-classification and management. Journal der Deutschen Dermatologischen Gesellschaft 8: 652-661.
6. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, et al. (2003) CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in radiation oncology13: 176-181.
7. Disel U, Gürkut Ö, Abali H, Kaleagasi H, Mertsoylu H, et al. (2010) Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutaneous and Ocular Toxicology 29: 140-142.
8. Nagore Enguidanos E, Sanchez-Motilla JM, Insa Molla A, Febrer MI, (1998) Palmar-plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy: Successful treatment with pyridoxine. Medicina Cutanea Ibero-Latino-Americana 26: 35-38.
9. Janusch M, Fischer M, Marsch W, Holzhausen H, Kegel T, et al. (2006) The hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 16: 494-499.
10. Corrie PG, Bulusu R, Wilson CB, Armstrong G, Bond S, et al. (2012) A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer 107: 585-587.
11. Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, et al. (2010) Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. Journal of clinical oncology 28: 3824-3829.
12. Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, et al. (2010) A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 116: 4735-4743.
13. Chalermchai T, Tantiphlachiva K, Suwanrusme H, Voravud N, Sriuranpong V, (2010) Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Asia-Pacific Journal of Clinical Oncology 6: 155-160.
14. Fang XH, Wu Q, Han XM, Cao TH, Liu LJ, et al. (2010) High dose pyridoxine for the prevention of hand-foot syndrome caused by capecitabine. Oncology 30: 1081-1082.
15. ClinicalTrials.gov website. Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer. Available: http://www.clinicaltrials.gov/ct2/show/NCT00486213?term=pyridoxine&rank=9. Accessed 2013 Feb 25.
16. Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available: http://handbook.cochrane.org. Accessed 2013 Mar 4.
17. Collaboration RTC (2011) Review Manager (RevMan). 5.1. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration.
18. Denda M, Inoue K, Fuziwara S, Denda S, (2002) P2X Purinergic Receptor Antagonist Accelerates Skin Barrier Repair and Prevents Epidermal Hyperplasia Induced by Skin Barrier Disruption. Journal of investigative dermatology 119: 1034-1040.
19. Banfield G, Crate I, Griffiths C, (1995) Long-term sequelae of Palmar-Plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. Journal of the Royal Society of Medicine 88: 356-357.
20. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, et al. (1990) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Investigational New Drugs 8: 57-63.
21. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, et al. (1995) Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75: 2169-2173.
22. Mortimer JE, Anderson I, (1990) Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemotherapy and Pharmacology 26: 449-452.
23. Portal I, Cardenal F, Garcia-del-Muro X, (1994) Etoposide-related acral erythema. Cancer Chemotherapy and Pharmacology 34: 181.
24. Vukelja SJ, Lombardo FA, James WD, Weiss RB, (1989) Pyroxidine for the Palmar-Plantar Erythrodysesthesia Syndrome. Annals of Internal Medicine 111: 688-689.
25. Vukelja SJ, Baker WJ, Burris HA, Keeling JH, Von HD, (1993) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. Journal of the National Cancer Institute 85: 1432-1433.
26. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, et al. (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clinical Cancer Research 15: 1411-1416.
27. Hau P, Fabel K, Baumgart U, Rümmele P, Grauer O, et al. (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100: 1199-1207.
28. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, et al. (1998) Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4: 1567-1571.
29. Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, et al. (1992) Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Investigation 10: 1-9.